Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients

Area of Science:

• Hematology
• Cardiology
• Oncology

Background:

• Hematopoietic stem cell transplantation (HSCT) offers curative potential for various diseases.
• Treatment-related complications, including graft-versus-host disease (GvHD) and cardiovascular complications (CVC), significantly impact HSCT outcomes.
• CVC is a growing concern, especially in long-term HSCT survivors.

Purpose of the Study:

• To review the current understanding of cardiovascular complications (CVC) following hematopoietic stem cell transplantation (HSCT).
• To identify risk factors and current management strategies for HSCT-related CVC.
• To highlight the need for further research into the mechanisms and treatment of CVC post-HSCT.

Main Methods:

• Literature review of studies on cardiovascular complications in hematopoietic stem cell transplantation patients.
• Analysis of risk factors including cardiotoxic induction treatments, conditioning regimens, and post-transplant comorbidities like GvHD.
• Evaluation of current diagnostic and therapeutic approaches for CVC.

Main Results:

• Cardiotoxic treatments, conditioning regimens (e.g., cyclophosphamide), and GvHD are significant contributors to CVC.
• Cardiac function evaluation (echocardiography, biomarkers) is vital pre- and post-HSCT.
• Pharmacological interventions like ACE inhibitors, ARBs, and beta-blockers show potential for managing CVC.

Conclusions:

• Cardiovascular complications (CVC) are a critical challenge in hematopoietic stem cell transplantation (HSCT), affecting long-term survivors.
• Routine cardiac monitoring and risk factor management are essential for HSCT patients.
• There is an urgent need for comprehensive preclinical and clinical research to elucidate CVC mechanisms and develop targeted therapies.